Advanced in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)

Dr. Naveed M. Chowhan

Hematology Oncology | Oncology
Jackson County Schneck Memorial Hospital
411 W Tipton St, Schneck Medical Center, 
Seymour, IN 
Accepting New Patients
43 Years of Experience
Advanced in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Jackson County Schneck Memorial Hospital
411 W Tipton St, Schneck Medical Center, 
Seymour, IN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Naveed Chowhan is a Hematologist Oncology specialist and an Oncologist in Seymour, Indiana. Dr. Chowhan has been practicing medicine for over 43 years and is rated as an Advanced provider by MediFind in the treatment of Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET). His top areas of expertise are Hemangioma Thrombocytopenia Syndrome, Thrombocytopenia, Non-Hodgkin Lymphoma, Hereditary Resistance to Anti-Vitamin K, and Bone Marrow Aspiration. Dr. Chowhan is currently accepting new patients.

His clinical research consists of co-authoring 2 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year
1982
Specialties
Hematology Oncology
Oncology
Licenses
Internal Medicine in IN
Hospital Affiliations
Schneck Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
MDwise
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

JACKSON COUNTY SCHNECK MEMORIAL HOSPITAL
411 W Tipton St, Schneck Medical Center, Seymour, IN 47274

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Enrollment Status: Active_not_recruiting
Publish Date: September 05, 2025
Intervention Type: Drug
Study Drug: Entrectinib
Study Phase: Phase 2
A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)
A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)
Enrollment Status: Active_not_recruiting
Publish Date: November 14, 2024
Intervention Type: Drug, Other
Study Drug: Ribociclib
Study Phase: Phase 3
An Open-Label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
An Open-Label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Enrollment Status: Active_not_recruiting
Publish Date: April 18, 2024
Intervention Type: Drug
Study Drugs: Lasofoxifene, Fulvestrant
Study Phase: Phase 2
A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Two-part, Open-label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan Versus Irinotecan for Second Line Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
A Two-part, Open-label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan Versus Irinotecan for Second Line Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: December 09, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2/Phase 3
A Phase 1-2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profile of 0.1% Uracil Topical Cream (UTC) in the Prevention of Hand-Foot Syndrome (HFS) in Patients With Metastatic Breast Cancer Treated With Capecitabine
A Phase 1-2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profile of 0.1% Uracil Topical Cream (UTC) in the Prevention of Hand-Foot Syndrome (HFS) in Patients With Metastatic Breast Cancer Treated With Capecitabine
Enrollment Status: Completed
Publish Date: October 08, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 5 Less Clinical Trials

2 Total Publications

Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial.
Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: May 18, 2020
Similar Doctors
Distinguished in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. John L. Huber
Hematology Oncology | Hematology | Oncology
Distinguished in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. John L. Huber
Hematology Oncology | Hematology | Oncology

Baptist Health Medical Group Inc

4003 Kresge Way, Suite 500, 
Louisville, KY 
 (51.3 miles away)
502-897-1166
Languages Spoken:
English
See accepted insurances
Accepting New Patients

John Huber is a Hematologist Oncology specialist and a Hematologist in Louisville, Kentucky. Dr. Huber is rated as a Distinguished provider by MediFind in the treatment of Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET). His top areas of expertise are Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), Chronic Lymphocytic Leukemia (CLL), Intraductal Papilloma, and Bone Marrow Aspiration. Dr. Huber is currently accepting new patients.

Distinguished in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. Paul R. Helft
Hematology Oncology | Oncology
Distinguished in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. Paul R. Helft
Hematology Oncology | Oncology

University Medical Diagnostic Associates Inc

550 N University Blvd, 
Indianapolis, IN 
 (58.7 miles away)
217-274-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Paul Helft is a Hematologist Oncology specialist and an Oncologist in Indianapolis, Indiana. Dr. Helft is rated as a Distinguished provider by MediFind in the treatment of Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET). His top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Neuroendocrine Tumor, and Lynch Syndrome. Dr. Helft is currently accepting new patients.

Advanced in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. Patrick J. Loehrer
Hematology Oncology | Oncology
Advanced in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. Patrick J. Loehrer
Hematology Oncology | Oncology

University Medical Diagnostic Associates Inc

550 N University Blvd, 
Indianapolis, IN 
 (58.7 miles away)
217-274-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Patrick Loehrer is a Hematologist Oncology specialist and an Oncologist in Indianapolis, Indiana. Dr. Loehrer is rated as an Elite provider by MediFind in the treatment of Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET). His top areas of expertise are Thymic Epithelial Tumor, Colorectal Cancer, Pancreatic Cancer, Pancreaticoduodenectomy, and Thymectomy. Dr. Loehrer is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chowhan's expertise for a condition
ConditionClose
    View All 49 Distinguished Conditions
    View All 82 Advanced Conditions
    View All 160 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile